Clinical
Macular telangiectasia (MacTel)
Macular telangiectasia type 2 (MacTel) is a bilateral, slowly progressive neurodegenerative condition of unknown etiology. The natural course of MacTel is characterized by photoreceptor atrophy, perifoveal vascular abnormalities, and gradual loss of central vision. There are no FDA-approved treatments for this disorder. There is a large body of evidence to support the use of ciliary neurotrophic factor (CNTF) as a potential therapy for retinal degenerative diseases, however, it is significantly handicapped by its extremely short half-life. Neurotech Pharmaceuticals, Inc. has developed the NT-501 device to provide sustained delivery of CNTF for treatment retinal degenerative diseases, including MacTel. The NT-501 device is implanted into the vitreous cavity with a simple surgical procedure performed under local/MAC anesthesia.
MacTel Phase 3 Clinical Sites
International sites
Australia
France
Germany
United Kingdom
.jpg)
MacTel Studies
Bilateral Implant and Extension Studies
Glaucoma Studies
Glaucoma is a disease of the optic nerve, characterized by the selective loss of retinal ganglion cells and associated reduction in the visual field. When the nerve is damaged, visual information loses the medium by which it is transferred to the brain. Over time, vision is slowly lost. All currently approved glaucoma medications are directed toward lowering intraocular pressure. However, another potential approach is protection against retinal ganglion cell atrophy. The protective effect of CNTF on retinal ganglion cells in laser-induced ocular hypertensive models has been previously demonstrated. Neurotech Pharmaceuticals is investigating the CNTF-producing NT-501 device for treatment of glaucoma.